The safety and efficacy of Lenvatinib for patients with unresectable hepatocellular carcinoma on practical medicine after the approval
Not Applicable
Completed
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000034333
- Lead Sponsor
- ational Hospital Organization Kyoto Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnant woman Woman who may be pregnant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Objective response rate Adverse events Drug withdrawal Drug interruption Dose reduction Dose intensity